AstraZeneca (AZ) has obtained a global online license from Nanoform to use their STARMAP artificial intelligence (AI) technology for molecule screening. STARMAP is a digital AI version of Nanoform's Controlled Expansion of Supercritical Solutions (CESS) technology, enabling the creation of API nanoparticles directly from a solution. The online technology, which successfully completed technology evaluation in clinical candidate feasibility studies, will allow clients to perform large numbers of in-silico CESS experiments via their desktops, enhancing molecule selection for drug discovery and lifecycle management. It aims to improve bioavailability, differentiation, formulation, and patient adherence. In return, Nanoform gains access to compound libraries and collaboratively explores product development concepts with AZ. Their partnership began with a technology evaluation in 2019, focusing on delivering value across the pharmaceutical value chain.